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Abstract 
Background 
Lung cancer is the leading cause of largest number of deaths worldwide and lung 
adenocarcinoma is the most common form of lung cancer. In order to understand the 
molecular basis of lung adenocarcinoma, integrative analyses have been performed by 
using genomics, transcriptomics, epigenomics and clinical data. Besides, molecular 
prognostic signatures have been generated for lung adenocarcinoma by using gene 
expression levels in tumor samples. However, we need signatures including different 
types of molecular data, even cohort or patient-based biomarkers which are candidate 
of molecular targeting. 
Results 
We built an R pipeline to carry out an integrated meta-analysis of the genomic 
alterations including single-nucleotide variations and the copy number variations, 
transcriptomics variations through RNA-seq and clinical data of patients with lung 
adenocarcinoma in The Cancer Genome Atlas project. We integrated significant genes 
including single-nucleotide variations or the copy number variations, differentially 
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expressed genes and those in active subnetworks to construct prognosis signature. Cox 
proportional hazards model with Lasso penalty and LOOCV was used to identify best 
gene signature among different gene categories.  
We determined 12-gene signature (BCHE, CCNA1, CYP24A1, DEPTOR, MASP2, 
MGLL, MYO1A, PODXL2, RAPGEF3, SGK2, TNNI2, ZBTB16) for prognostic risk 
prediction based on overall survival time of the patients with lung adenocarcinoma. The 
patients in both training and test data were clustered into high-risk and low-risk groups 
by using risk scores of the patients calculated based on selected gene signature. Overall 
survival probability of these risk groups was highly significantly different for both 
training and test datasets. 
Conclusions 
These 12-gene signature could predict the prognostic risk of the patients with lung 
adenocarcinoma in TCGA and they are potential predictors for the survival-based risk 
clustering of the patients with lung adenocarcinoma. These genes can be used to cluster 
patients based on molecular nature and the best candidates of drugs for the patient 
clusters can be proposed. These genes also have high potential for targeted cancer 
therapy of patients with lung adenocarcinoma. 
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Background 
Lung cancer is the most common cancer and responsible for largest number of deaths 
worldwide with 1.8 million deaths, 18.4% of the total (IARC, 2018). Lung cancer is 
categorized into two main categories: non-small cell lung cancer (NSCLC) which occurs 
in 85% of patients and small cell lung cancer (SCLC) in 15% of cases. NSCLC is grouped 
into 3 histological sub-types: lung adenocarcinoma (LUAD) which is most common 
form of lung cancer, lung squamous cell carcinoma (LUSC) and large cell carcinoma 
(Travis, 2011).  
Integration of different types of molecular data has been used to characterize molecular 
basis of lung cancer and to determine clinical status of patients. Shi et al. analyzed 101 
LUAD samples by using data from different levels -DNA mutations, gene expression 
profile, copy number variations and DNA methylation- in order to identify the relation 
between genomic status and clinical status. They determined deleterious mutations at 
ZKSCAN1 and POU4F2 genes which are two novel candidate driver genes (Shi, 2016). 
Furthermore, recent studies have been performed to generate new methods to analyze 
integrative cancer data. Berger et al. proposed a new method called expression-based 
variant-impact phenotyping (eVIP) using differentially expressed genes (DEGs) to 
distinguish driver mutations from passenger mutations. They characterized 194 
somatic mutations related with primary LUAD and claimed that 69% of mutations were 
mutations. They found the driver mutations in LUAD are EGFR (p.S645C), ERBB2 
(p.S418T), ARAF (p.S214C) and ARAF (p.S214F) (Berger, 2016). TCGA network 
analyzed 230 LUAD samples using mRNA, microRNA and DNA sequencing integrated 
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with copy number, methylation and proteomic data (The Cancer Genome Atlas 
Research Network, 2014) and reported the samples with high rates of somatic 
mutation. Eighteen genes with high mutation load were reported such as RIT1 
activating mutations and MGA loss-of-function mutations. They also identified 
aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and MAPK and 
PI(3)K pathway activity (The Cancer Genome Atlas Research Network, 2014). Deng Z. 
et al., presented genomic alterations in LUAD samples from TCGA and found the 
significantly aberrant CNV segments which are associated with the immune system and 
63 mutated genes associated with lung cancer signaling related to cancer progression. 
They identified important mutations of the PI3K protein family members include 
PIK3C2B, PIK3CA, PIK3R1 (Deng, 2017). 
Recently, studies have been performed to generate gene signatures predicting 
prognosis risk of patients with lung adenocarcinoma. In 2016, Krzystanek et al. 
identified 7-gene signature by using microarray data of early stage lung 
adenocarcinoma from GEO datasets. The genes (ADAM10, DLGAP5, RAD51AP1, 
FGFR10P, NCGAP, KIF15, ASPM) which have high hazards ratios showed significant 
results at cox regression analysis and Kaplan-Meier survival plots (Krzystanek, 2016). 
Shukla et.al. identified 96 genes including five long noncoding RNAs (lncRNAs) among 
training data which had prognostic association at test data, by using lung 
adenocarcinoma RNA-seq and clinical data from TCGA (Shukla, 2017). Shi et.al. 
studied on long noncoding RNAs (lncRNAs) expression signature model to predict 
stage I lung adenocarcinoma from TCGA and determined 31-lncRNA signature to 
predict overall survival in patients with LUAD (Shi, 2018). Zhao et. al. used gene 
expression profiles from TCGA and identified 20 genes which were significantly 
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associated with the overall survival (OS). When they combined with GEO data set, they 
obtained four genes, FUT4, SLC25A42, IGFBP1, and KLHDC8B as common (Zhao, 
2018). Li et. al. performed RNA-sequencing on LUAD tumor samples and normal tissue 
samples. They construct protein–protein interaction network by using DEGs which 
were intersection of GEO datasets and identified hub genes. Then, they test these genes 
on patient cohorts and TCGA data. They identified eight genes (DLGAP5, KIF11, 
RAD51AP1, CCNB1, AURKA, CDC6, OIP5 and NCAPG) which were closely related to 
survival in LUAD (Li, 2018). He et. al. studied on previous GEO datasets and TCGA 
data and they identified 8-gene prognostic signature (CDCP1, HMMR, TPX2, CIRBP, 
HLF, KBTBD7, SEC24B-AS1, and SH2B1) by using the step-wise multivariate Cox 
analysis. These genes were good predictors of survival between high-risk and low-risk 
groups of patients with early-stage NSCLC (He, 2019). The studies above determined 
different gene signatures for prognosis risk prediction by using different methods and 
presented different genes. Although, mostly gene expression data has been used for this 
purpose, we integrated SNVs, CNVs, DEGs and active subnetwork DEGs to generate 
gene signature for risk model by using LUAD data from The Cancer Genome Atlas 
(TCGA) database which provides simple nucleotide variation, gene expression, miRNA 
expression, DNA methylation, copy number variation and reverse phase protein array, 
clinical and biospecimen data from more than 10,000 cancer patients with 39 cancer 
types (Chang, 2013). 
In this study, we built an R pipeline (Figure 19) to perform an integrative analysis 
including SNVs and CNVs, differentially expressed genes and clinical data of patients 
with lung adenocarcinoma in TCGA. We generated different data categories by using 
significant SNVs, CNVs, DEGs and active subnetwork DEGs. Multivariate Cox 
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proportional hazards model with Lasso penalty and LOOCV was used to identify best 
gene signature among different gene categories. We generated 12-gene signature 
(BCHE, CCNA1, CYP24A1, DEPTOR, MASP2, MGLL, MYO1A, PODXL2, RAPGEF3, 
SGK2, TNNI2, ZBTB16) for prognostic risk prediction based on overall survival time of 
the patients with lung adenocarcinoma. When we clustered patients into high-risk and 
low-risk groups, the survival analysis showed highly significant results for both training 
and test datasets. 
 
Results 
Identification of Significant Simple Nucleotide Variations 
Mutation data of LUAD patients as maf file generated by mutect pipeline was 
downloaded by TCGAbiolinks package and maftools package was used to subset 
original maf file by tumor sample barcodes of 55 LUAD patients and 510 LUAD 
patients. Then, significant mutations for both 55 and 510 LUAD patients were 
determined separately with their roles as tumor suppressor or oncogene by 
SomInaClust R package. In order to determine important genes including significant 
mutation clusters, we used SomInaClust R package. EGFR, KRAS, TP53, STK11, RB1 
and MGA genes were determined as candidate driver genes in tumor samples of 55 
LUAD patients (Figure 1). EGFR and KRAS genes were classified as oncogene and 
STK11, RB1 and MGA genes were classified as tumor suppressor. Although TP53 gene 
has both OG score and TSG score, TP53 was classified as tumor suppressor in Table 1 
depending on reference information of cancer gene census. EGFR, KRAS, TP53, STK11 
and RB1 have highly significant estimation. While EGFR and TP53 have higher number 
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of mutations, KRAS, STK11, RB1 and MGA have lower number of mutations. While 
EGFR, KRAS, TP53, STK11, RB1 are well known cancer related genes, MGA gene is not 
in cancer gene census. 
 
Figure 1. Pyramid plot of important mutated genes classified as oncogene (OG) or tumor 
suppressor gene (TSG) in tumor samples of 55 patients with LUAD 
Table 1. Significant mutated genes in 55 tumor samples 
Gene # Mutations Q value OG Score TSG Score Classification CGC*  
EGFR 11 1.57e-12 80 0 OG Dom 
KRAS 8 1.57e-12 100 0 OG Dom 
TP53 20 4.8e-07 62.5 55 TSG Rec 
STK11 7 0.000106 0 85.7 TSG Rec 
RB1 7 0.0049 0 71.4 TSG Rec 
MGA 6 0.0217 0 80 TSG NA 
* Cancer gene census (Dom: Dominant, Rec: Recessive) 
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Eighty-two genes as candidate driver genes in tumor samples of 510 LUAD patients 
(Table 2), including KRAS, TP53, EGFR, STK11, MGA and RB1 which were determined 
also in tumor samples of 55 LUAD patients (Figure 2). These genes include very well-
known cancer related oncogenes such as BRAF, ERBB2, AKT1 and PIK3CA with the 
genes which are not listed in cancer gene census list of COSMIC database (Table 2). 
 
Figure 2. Pyramid plot of top 40 important mutated genes classified as oncogene (OG) or 
tumor suppressor gene (TSG) in tumor samples of 510 patients with LUAD 
 
Table 2. Significant mutated genes in tumor samples of 510 patients with LUAD 
Gene # Mutations qDG OG Score TSG Score Classification CGC* 
KRAS 143 1.97e-250 97.8 0 OG Dom 
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TP53 253 2.52e-135 79.7 38 TSG Rec 
EGFR 73 8.97e-84 73.8 10 OG Dom 
STK11 83 4.6e-61 27.8 72 TSG Rec 
BRAF 44 8.07e-51 67.5 7.4 OG Dom 
RBM10 39 9.06e-31 0 78.9 TSG NA 
NF1 63 5.37e-25 0 54.2 TSG Rec 
MGA 52 6.46e-23 0 58.3 TSG NA 
SETD2 44 1.34e-20 16.7 58.1 TSG Rec 
RB1 32 4.99e-20 0 68.8 TSG Rec 
PIK3CA 27 1.36e-19 61.5 0 OG Dom 
ATM 48 5.18e-18 25 45.7 TSG Rec 
CTNNB1 21 3.32e-15 61.1 12.5 OG Dom 
ARID1A 30 1.76e-14 12.5 60 TSG Rec 
ARID2 29 2.83e-12 0 57.1 TSG Rec 
SMARCA4 48 2.23e-11 16.7 42.9 TSG Rec 
CSMD3 324 6.25e-10 0 17.5 NA NA 
ATF7IP 17 1.84e-08 0 71.4 TSG NA 
KEAP1 90 1.91e-08 9.8 24.1 TSG NA 
NFE2L2 14 2.83e-07 58.3 0 OG Dom 
KDM5C 16 1.76e-06 0 60 TSG Rec 
ERBB2 13 6.94e-06 55.6 14.3 OG Dom 
LRP1B 267 6.04e-05 0 15.6 NA Rec 
HMCN1 97 8.93e-05 0 24.1 TSG NA 
MAP2K1 9 0.000263 66.7 0 OG Dom 
APC 24 0.000272 0 37.5 TSG Rec 
PNISR 6 0.000626 0 83.3 TSG NA 
RPL5 7 0.000626 0 83.3 TSG Dom 
 10 
GNAS 19 0.000962 28.6 0 OG Dom 
COL11A1 129 0.00139 0 18.1 NA NA 
EPHA5 66 0.00221 0 23.4 TSG NA 
TTK 18 0.00221 0 41.2 TSG NA 
FBXW7 12 0.0028 40 50 TSG Rec 
DMD 99 0.00349 0 18.8 NA NA 
SMAD4 20 0.00379 30 35 TSG Rec 
FER 16 0.0043 0 46.2 TSG NA 
MARK1 21 0.0043 0 46.2 TSG NA 
TEP1 29 0.0043 0 46.2 TSG NA 
ATRX 35 0.00463 0 26.5 TSG Rec 
CDKN2A 21 0.00585 37.5 35 TSG Rec 
MYO9A 19 0.00615 0 42.9 TSG NA 
ZNF800 17 0.00615 0 42.9 TSG NA 
CMTR2 26 0.00674 0 55.6 TSG NA 
RASA1 9 0.00674 0 55.6 TSG NA 
CDKN1B 5 0.00674 0 80 TSG Rec 
DHX15 7 0.00674 0 80 TSG NA 
IQGAP2 28 0.00816 0 40 TSG NA 
LTN1 19 0.00816 0 40 TSG NA 
SMARCA1 19 0.00816 0 40 TSG NA 
SPTA1 164 0.00971 0 17.6 NA NA 
FHOD3 31 0.0122 0 30.4 TSG NA 
CPVL 8 0.0161 0 66.7 TSG NA 
MAP3K12 8 0.0161 0 66.7 TSG NA 
TOP2B 9 0.0161 0 66.7 TSG NA 
ROCK1 21 0.0163 0 35.3 TSG NA 
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PBRM1 12 0.0172 0 45.5 TSG Rec 
AKAP6 40 0.0195 0 28 TSG NA 
SENP1 3 0.0241 0 100 TSG NA 
SP1 4 0.0241 0 100 TSG NA 
WISP3 4 0.0241 0 100 TSG NA 
RAD50 13 0.0243 20 41.7 TSG NA 
COL28A1 19 0.0243 0 41.7 TSG NA 
SCAF8 18 0.0243 0 41.7 TSG NA 
STK31 19 0.0243 0 41.7 TSG NA 
IDH1 6 0.0248 40 25 TSG Dom 
USH2A 240 0.0263 0 13.2 NA NA 
YLPM1 23 0.0269 0 31.6 TSG NA 
IQUB 12 0.0272 0 57.1 TSG NA 
MARK2 10 0.0272 0 57.1 TSG NA 
NAA15 8 0.0272 0 57.1 TSG NA 
CDH10 99 0.028 0 16.4 NA NA 
AKT1 3 0.0296 66.7 0 OG Dom 
RAF1 7 0.031 66.7 0 OG Dom 
VPS13C 39 0.0332 0 25 TSG NA 
ZBBX 28 0.0333 0 30 TSG NA 
DST 67 0.0333 0 19.1 NA NA 
KMT2C 52 0.0388 0 18.8 NA Rec 
DGKB 38 0.0431 0 28.6 TSG NA 
MAP2K4 8 0.045 33.3 50 TSG Rec 
FBN2 93 0.045 0 20.5 TSG NA 
B2M 8 0.045 0 50 TSG Rec 
BAP1 8 0.045 0 50 TSG Rec 
* Cancer gene census (Dom: Dominant, Rec: Recessive) 
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Identification of Significant Copy Number Variations 
CNVs (Copy Number Variations) are important aberrations which results alterations in 
gene expression in tumorigenesis and tumor growth. In order to determine significant 
CNVs among tumor samples of 55 and 510 LUAD patients, gaia R package was used. 
Significant recurrent CNVs in tumor samples of 55 LUAD patients, over the q-value 
thresholds (0.01), are mostly observed on Chromosome 1, 8, 9, and 17. Chromosome 1 
has the highest number of amplifications followed by Chromosome 8. Chromosome 9 
has the highest number of deletions followed by Chromosome 17 as seen in Figure 3. 
Chromosome 1 has the highest number of gene aberration with 2006 amplified or 
deleted genes followed by Chromosome 8 with 1029 aberrant genes and Chromosome 
19 with 785 aberrant genes. Top ten significant amplified and deleted genes which are 
all from chromosome 1 are listed in Table 3. 
 
Figure 3. Significant CNVs on all chromosomes in tumor samples of 55 patients with 
LUAD 
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Table 3. Top ten significant deleted and amplified genes in tumor samples of 55 patients 
with LUAD 
Gene Symbol Aberration q-value Aberrant Region Gene Region 
RN7SKP285 Del 0.00474651 1:103501576-107318961 1:103523562-103523879 
RNPC3 Del 0.00474651 1:103501576-107318961 1:103525691-103555239 
AMY2B Del 0.00474651 1:103501576-107318961 1:103553815-103579534 
ACTG1P4 Del 0.00474651 1:103501576-107318961 1:103569553-103570674 
AMY2A Del 0.00474651 1:103501576-107318961 1:103616811-103625780 
AMY1A Del 0.00474651 1:103501576-107318961 1:103655290-103664554 
AC105272.1 Del 0.00474651 1:103501576-107318961 1:103668071-103668268 
AMY1B Del 0.00474651 1:103501576-107318961 1:103687415-103696680 
AMYP1 Del 0.00474651 1:103501576-107318961 1:103713723-103719871 
AMY1C Del 0.00474651 1:103501576-107318961 1:103750406-103758690 
PLEKHO1 Amp 0.00474651 1:150131878-150768299 1:150149183-150164720 
AC242988.2 Amp 0.00474651 1:150131878-150768299 1:150173049-150181429 
RN7SL480P Amp 0.00474651 1:150131878-150768299 1:150211632-150211925 
ANP32E Amp 0.00474651 1:150131878-150768299 1:150218417-150236156 
RNU2-17P Amp 0.00474651 1:150131878-150768299 1:150236967-150237156 
AC242988.1 Amp 0.00474651 1:150131878-150768299 1:150255095-150257286 
CA14 Amp 0.00474651 1:150131878-150768299 1:150257251-150265078 
APH1A Amp 0.00474651 1:150131878-150768299 1:150265399-150269580 
C1orf54 Amp 0.00474651 1:150131878-150768299 1:150268200-150280916 
CIART Amp 0.00474651 1:150131878-150768299 1:150282543-150287093 
 
 
Significant recurrent CNVs in tumor samples of 510 LUAD patients, over the q-value 
thresholds (0.01), are mostly observed on Chromosome 4, 9, 10, 11, 12, 13, 14, 16, 18 
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and 20. But Chromosome 11 has the highest number of aberrations followed by 
Chromosome 9, 16 and 18. Chromosome 4, 9, 10, 12 and 16 has mostly amplifications 
(Figure 4). The pattern of CNVs in tumor samples of 510 patients has a marked 
difference from the CNV pattern in tumor samples of 55 patients (Figure 3). 
Chromosome 1 has the highest number of gene aberration with 3124 amplified or 
deleted genes followed by Chromosome 6 with 2911 aberrant genes and Chromosome 
3 with 2149 aberrant genes. Top ten significant amplified and deleted genes which are 
all from chromosome 1 are showed in Table 4.  
 
Figure 4. Significant CNVs on all chromosomes in tumor samples of 510 patients with 
LUAD 
 
 
Table 4. Top ten significant amplified and deleted genes in 510 LUAD patients 
Gene Symbol Aberration q-value Aberrant Region Gene Region 
AL359821.1 Del 0.0029609 1:71621685-71778398 1:71738173-71738354 
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GDI2P2 Del 0.0029609 1:71928758-119984738 1:72274552-72275159 
AL513166.2 Del 0.0029609 1:71928758-119984738 1:72283170-72753772 
RPL31P12 Del 0.0029609 1:71928758-119984738 1:72301472-72301829 
AL583808.1 Del 0.0029609 1:71928758-119984738 1:72636547-72899240 
RNU6-1246P Del 0.0029609 1:71928758-119984738 1:72717663-72717769 
AL583808.2 Del 0.0029609 1:71928758-119984738 1:72765031-72791282 
AL583808.3 Del 0.0029609 1:71928758-119984738 1:72793104-72854475 
AL732618.1 Del 0.0029609 1:71928758-119984738 1:72979014-72979314 
KRT8P21 Del 0.0029609 1:71928758-119984738 1:73104792-73106282 
SF3B4 Amp 0.0029609 1:149907993-247650984 1:149923317-149927803 
MTMR11 Amp 0.0029609 1:149907993-247650984 1:149928651-149936879 
OTUD7B Amp 0.0029609 1:149907993-247650984 1:149937812-150010726 
AC244033.2 Amp 0.0029609 1:149907993-247650984 1:150045660-150067701 
AC244033.1 Amp 0.0029609 1:149907993-247650984 1:150053864-150055034 
VPS45 Amp 0.0029609 1:149907993-247650984 1:150067279-150145329 
PLEKHO1 Amp 0.0029609 1:149907993-247650984 1:150149183-150164720 
AC242988.2 Amp 0.0029609 1:149907993-247650984 1:150173049-150181429 
RN7SL480P Amp 0.0029609 1:149907993-247650984 1:150211632-150211925 
ANP32E Amp 0.0029609 1:149907993-247650984 1:150218417-150236156 
 
Differential Expression Analysis (DEA) 
The Transcriptome Profiling data of LUAD patients in mRNA expression level (as 
unnormalized HTSeq raw counts), was downloaded by TCGABiolinks R package. 
Differentially expressed genes were determined with FDR adjusted p-values (q-values) 
in tumor samples (TP) of 55 patients with LUAD compared to normal samples (NT) of 
the same patients by limma-voom method using limma and edgeR R packages. The 
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volcano plot in Figure 5, shows the differentially expressed genes (DEGs) as dots of 
which black ones represent the genes which have differential expression less than two-
fold and not significant while red ones represent upregulated and green ones 
downregulated more than two-fold (log2=1) significantly (q value < 0.01). As the result 
of this analysis, 3575 genes were dysregulated more than two-fold with 0.01 q-value 
significance. 
 
Figure 5. Volcano plot of differentially expressed genes in tumor samples of 55 patients 
with LUAD. 
 
As the result of DEA, differentially expressed genes (DEGs) are determined with their 
log Fold Change (logFC), adjusted p-value (q-value), entrez gene IDs and HGNC 
symbols after enrichment analysis. The top 10 down-regulated and up-regulated genes 
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are showed in Table 5 and Table 6. The list of DEGs were used for pathway analysis and 
active subnetwork analysis. 
 
Table 5. Top ten significant down-regulated genes in tumor samples of 55 LUAD patients 
ensembl_gene_id entrezgene hgnc_symbol logFC adj.P.Val 
ENSG00000182010 219790 RTKN2 -4.52455117194123 1.07397390772473e-42 
ENSG00000158764 142683 ITLN2 -7.4364942528429 3.19924465283634e-41 
ENSG00000102683 6445 SGCG -4.10485571819757 4.07515928515459e-41 
ENSG00000198873 2869 GRK5 -2.65790712992412 4.07515928515459e-41 
ENSG00000107742 9806 SPOCK2 -3.56967403596283 3.85300139768808e-40 
ENSG00000170323 2167 FABP4 -5.72790493543673 1.03033381509032e-39 
ENSG00000135063 9413 FAM189A2 -3.53046742312343 1.03117504787973e-39 
ENSG00000186994 256949 KANK3 -3.1101996380779 1.15468325581686e-39 
ENSG00000150625 2823 GPM6A -5.17438700689996 1.5648953870669e-39 
ENSG00000154721 58494 JAM2 -2.50261146610761 1.92231892168565e-39 
 
Table 6. Top ten significant up-regulated genes in tumor samples of 55 LUAD patients 
ensembl_gene_id entrezgene hgnc_symbol logFC adj.P.Val 
ENSG00000183010 5831 PYCR1 3.5139225242735 3.06017765569688e-41 
ENSG00000059573 5832 ALDH18A1 1.68852856318992 6.30895314373162e-38 
ENSG00000164466 94081 SFXN1 1.5322079314688 5.01920971916517e-37 
ENSG00000135052 51280 GOLM1 2.51608337184892 1.73125209540521e-35 
ENSG00000180198 1104 RCC1 1.62119814668367 1.82637777402036e-34 
ENSG00000155660 9601 PDIA4 1.6848754492746 2.37855372052335e-34 
ENSG00000096063 6732 SRPK1 1.62823462104507 2.66740561460568e-34 
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ENSG00000128050 10606 PAICS 1.65390171937903 4.22169230063646e-31 
ENSG00000111344 8437 RASAL1 3.57173273242386 1.08251787193746e-30 
ENSG00000173457 26472 PPP1R14B 1.86684316566064 7.07845976872399e-30 
 
Active Subnetwork and Pathway Analysis 
The output of Differentially Expression Analysis (DEA) containing differentially 
expressed genes with their Ensembl IDs and adjusted p-values (q-values) were used as 
input of DEsubs R package. The active subnetworks of differentially expressed genes in 
tumor samples of both 55 LUAD patients were determined by DEsubs package and 
results were represented as graphs at subnetwork and organism levels. DEsubs package 
identified 35 subnetworks including 192 genes, 14 of them including more than three 
genes, 8 of them including three genes and the others including two genes. In Figure 6, 
the top ten significant genes which play role in determined subnetworks are 
represented with their q-values. These genes are FABP4, WNT3A, EDNRB, TEK, 
AGER, EPAS1, ACADL, PDIA4, ANGPT4, KL. In this analysis, 35 subnetworks were 
determined and the first three subnetworks are presented in Figure 7, 8 and 9. When 
we look at the subnetworks’ graphs, in subnetwork 1 (Figure 7), the prominent genes 
are WNT genes which are members of WNT pathway, a major evolutionary conserved 
signaling pathway playing role in cell differentiation, cell migration and organogenesis 
during development and highly related to lung cancer; in subnetwork 3 (Figure 9), the 
prominent gene is AKT3 which is one of the AKT family members which play role in 
tumorigenesis and are modulators of several tumors. The pathways of subnetwork 
genes are mostly cancer related pathways such as melanoma, glioma, colorectal cancer, 
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chronic myeloid leukemia, basal cell carcinoma, apoptosis, erbb signaling, jak-stat 
signaling and map kinase signaling pathways (Figure 10). 
 
 
Figure 6. Top 10 significant subnetwork genes in tumor samples of 55 LUAD patients 
 
 
Figure 7. Graph of subnetwork 1 from 55 LUAD patients 
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Figure 8. Graph of subnetwork 2 from 55 LUAD patients 
 
 
Figure 9. Graph of subnetwork 3 from 55 LUAD patients 
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Figure 10. KEGG pathways which includes active subnetwork genes of 55 patients with 
LUAD 
Statistical Analysis 
In order to identify a molecular prognosis risk model, the clinical data of all patients in 
TCGA LUAD project (Table 7) was downloaded by TCGAbiolinks R package and 
separated as training data of 55 LUAD patients who have paired samples for RNAseq 
data and used for gene signature construction; and test data of remaining 422 LUAD 
patients after removing patients who have missing values in clinical data. Different 
gene signatures were generated from the genes which have prognostic ability. The 
univariate cox regression analysis was performed for significant SNV genes, significant 
CNV genes, significant DEGs and active subnetwork DEGs in tumor samples of 55 
patients with LUAD. There were 38 CNV genes, 463 DEGs and 37 subnetwork DEGs 
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(DEsubs) with prognostic ability after univariate analysis and logRank test (p <0.05). 
SNV genes did not have significant prognostic ability. Then different data categories 
(DEGs; DEsubs; CNVs; CNVs + DEGs, CNVs + DEsubs; CNVs + DEGs + SNVs; CNVs 
+ DEsubs + SNVs) were generated by using significant prognostic genes. These data 
categories underwent the Cox proportional hazards regression with Lasso penalty and 
LOOCV. Gene models from different categories were generated by using glmnet R 
package which gives active genes with their coefficients. The genes in the models were 
DEPTOR, ZBTB16, BCHE, MGLL, MASP2, TNNI2, RAPGEF3, SGK2, MYO1A, 
CYP24A1, PODXL2, CCNA1 from DEGs category; THRA, RAPGEF3, LAMB2 from 
DEsubs category; SNX13, AC080080.1, RNMTL1P2, AC080080.2 from CNVs 
category; THRA, RAPGEF3, LAMB2 from CNVs + DEsubs. The genes in CNVs + DEGs 
and CNVs + DEGs + SNVs categories were same with the genes in DEGs category; the 
genes in CNVs + DEsubs + SNVs were in the CNVs + DEsubs category. Then, c-index 
analysis was performed to identify the survival predictive ability of the gene models 
identified from different categories in Figure 11. The higher c-index score was 0.858 
from DEGs gene model. This gene model was chosen as best candidate prognosis gene 
signature for LUAD. 
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Table 7. Summary of clinical features of 55 and 510 patients with LUAD 
Category 
Number 
55 patients 510 patients 
Age at diagnosis (median; range) 66 (42-86) 66 (33-88) 
Gender   
   Female 33 273 
   Male 22 237 
Tumor stage   
   I 28 275 
   II 12 119 
   III 12 84 
   IV 2 25 
   NA 1 7 
Vital status   
   Alive 31 326 
   Dead 24 184 
 
 
Figure 11. The c-index of different gene categories in training data and selected signature 
in testing data. 
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Multivariate Cox regression analysis was performed for the genes in the chosen gene 
signature and risk scores of each patient in training data (55 LUAD patients) were 
calculated by using coefficient values and normalized expression values (log2+1) in 
tumor samples. Then the patients were clustered into high-risk and low-risk groups by 
using maxstat (maximally selected rank statistics) method based on optimal cutpoints 
for numerical variables by using survminer R package. When we performed Kaplan-
Meier (KM) survival analysis to demonstrate the overall survival of risk groups 
stratified based on gene signature, patients with high-risk score demonstrated poor 
overall survival (p < 0.0001) than those with low-risk score in training dataset (Figure 
12). 
 
Figure 12. Risk clustering and Kaplan-Meier survival analysis of the signature for 
training data 
 
The ROC curve analysis was performed to compare sensitivity and specificity of the 
predictive ability of risk score based on chosen gene signature. AUC values were 0.883 
for 1-year, 0.813 for 2-year, 0.943 for 5-year and 0.976 for 10-year survival prediction 
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(Figure 13a). These high AUC values showed that the risk scores calculated based on 
chosen gene signature can highly predict the overall survival. 
  
Figure 13. ROC curve analysis for 1, 2, 5 and 10-year survival prediction by the signature 
in both training and test data 
 
When we performed the correlation analysis between tumor stages, mutation counts 
and gene expressions of signature genes, there was a significant difference of tumor 
stages between risk groups although there was no difference of total SNV mutation 
count between groups (Figure 14). However, as expected gene expression levels were 
significantly different between high-risk and low-risk groups in training data (55 LUAD 
patients) (Figure 15). The expression levels of the BCHE, DEPTOR, MASP2, MGLL, 
MYO1A, PODXL2, RAPGEF3, SGK2, TNNI2, and ZBTB16, genes were lower in high-
risk group while the expression levels of the CCNA1 and CYP24A1 genes were higher in 
high-risk group (Figure 15). 
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Figure 14. Correlation analysis between risk groups and total mutation count and tumor 
stage in tumor samples of training data 
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Figure 15. Violin plot showing the expression levels of the signature genes between low-
risk and high-risk groups in tumor samples of training data 
 
In order to validate our signature, we calculated c-index for the prediction of overall 
survival of the 442 TCGA patients with LUAD (test data) and the c-index was 0.591 
which is lower than the c-index of training data (0.858). Then, multivariate cox 
regression analysis was performed for the signature genes in test data. The risk score 
for each patient was calculated by adding the multiplication of normalized gene 
expression level in tumor samples and multivariate cox regression coefficient value of 
each gene in signature. Patients in test dataset were divided into high-risk and low-risk 
groups by using maxstat (maximally selected rank statistics) method from using 
survminer R package (Figure 16a). Patients in high-risk group had poor overall survival 
significantly (p < 0.00055). The ROC curve analysis was performed to compare 
sensitivity and specificity of the predictive ability of risk score in the test dataset. AUC 
values were 0.479 for 1-year, 0.571 for 2-year, 0.622 for 5-year and 0.676 for 10-year 
survival prediction (Figure 13b). The AUC values of risk scores calculated based on 
chosen gene signature were very low according to the AUC values of training data. 
Although the survival predictive ability (c-index) of our gene signature and AUC values 
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of risk score in test data was low, our 12-gene signature could separate patients into two 
groups which have significant overall survival difference (Figure 16b). 
 
 
Figure 16. Risk clustering and Kaplan-Meier survival analysis of the signature for test 
data 
 
We performed the correlation analysis between tumor stages, mutation counts and 
gene expressions of signature genes for test data, there was a slight significant 
difference of tumor stages between risk groups although there was no difference of total 
SNV mutation count between groups (Figure 17). The gene expression levels of 6 
signature genes (BCHE, CCNA1, DEPTOR, MASP2, MGLL, TNNI2) were significantly 
different between high-risk and low-risk groups however, the gene expression levels of 
other 6 signature genes (CYP24A1, MYO1A, PODXL2, RAPGEF3, SGK2, ZBTB16) do 
not have significant difference in test data. The expression levels of the CCNA1 and 
TNNI2 genes were lower in high-risk group while the expression levels of the BCHE, 
DEPTOR, MASP2 and MGLL genes were higher in high-risk group (Figure 18). 
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Figure 17. Correlation analysis between risk groups and total mutation count and tumor 
stage in tumor samples of test data 
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Figure 18. Violin plot showing the expression levels of the signature genes between low-
risk and high-risk groups in tumor samples of test data 
 
Discussion 
Lung adenocarcinoma (LUAD) is the most common form of lung cancer which is most 
common cancer and responsible for largest number of deaths worldwide. In order to 
characterize genomic and transcriptomic abnormalities of lung cancer and to 
determine clinical status of patients, integrative analyses have been performed by using 
different types of molecular data. Recently, prognosis risk signatures have been 
generated to cluster patients with lung adenocarcinoma. However, mostly gene 
expression data has been used for this purpose. 
In this study, we performed an integrative analysis by using level-3 data of SNVs, CNVs 
and RNAseq data of patients with lung adenocarcinoma in TCGA project. We aimed to 
identify genomic and transcriptomic abnormalities that might be used to generate a 
molecular signature. We determined significant mutated genes; amplified and deleted 
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genes; and differentially expressed genes (DEGs) significantly and their active 
subnetworks by using R packages. Then we performed univariate and multivariate Cox 
Proportional Hazards Regression (CPHR) analysis with LOOCV and Lasso penalty to 
identify predictor genes on survival time of patients with lung adenocarcinoma. 
We identified 6 and 82 mutated genes which are candidate driver genes in tumor 
samples of 55 LUAD patients and those of 510 LUAD patients, respectively. KRAS and 
EGFR oncogenes with TP53, STK11, RB1 and MGA tumor suppressors were mutated 
significantly in small cohort of patients. The mutated 82 genes of big cohort of patients 
include the 6 genes above and also previously identified lung adenocarcinoma related 
genes such as KRAS, TP53, STK11, RB1, NF1, RMB10, BRAF, KEAP1, CDKN2A, SETD2, 
ARID1A, SMARCA4 and MGA (The Cancer Genome Atlas Research Network, 2014); 
EGFR and ERBB2 (The Cancer Genome Atlas Research Network, 2014; Berger, 2016); 
and PIK3CA (The Cancer Genome Atlas Research Network, 2014; Deng, 2017). Besides, 
MAP2K1 and MAP2K4 mutations can be related with MAPK pathway activity as 
identified in TCGA lung adenocarcinoma original article (The Cancer Genome Atlas 
Research Network, 2014). Loss-of-function MGA mutations with MYC amplification in 
lung adenocarcinoma have been newly described (The Cancer Genome Atlas Research 
Network, 2014) and MGA gene was identified by SomInaClust analysis in our study. 
MGA, encodes MAX gene-associated protein which is a MYC-interacting transcription 
factor and antagonizes the transcriptional regulation of MYC involved in cancer 
processes (Romero, 2014). 
We identified amplified and deleted genes which have copy number variations in tumor 
samples of patients with lung adenocarcinoma. We identified significant copy number 
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altered genes which play role in immune system pathways, metabolism pathways with 
small cell lung cancer pathway and molecular mechanism of cancer pathway. We 
analyzed differentially gene expression in tumor samples compared to paired normal 
samples of 55 patients with lung adenocarcinoma and 3575 genes were dysregulated 
more than two-fold, significantly (q-value < 0.01). The upregulated genes mostly play 
role in cell cycle and proliferation pathways such as G2/M damage checkpoint 
regulation, cell cycle control of chromosomal replication, ATM signaling, hereditary 
breast cancer signaling, bladder cancer signaling and HIF1 signaling pathways. The 
downregulated genes play role in cAMP-mediated signaling, g-protein coupled receptor 
signaling, Gαi signaling and other immune system pathways such as complement 
system, granulocyte/agranulocyte adhesion and diapedesis, dendritic cell maturation 
and T helper cell differentiation. Then we determined differentially expressed genes 
(DEGs) in active subnetworks of PPI network in tumor samples and we identified 192 
DEGs in 35 subnetworks. These genes play role in mostly cancer related pathways such 
as melanoma, glioma, colorectal cancer, chronic myeloid leukemia, basal cell 
carcinoma, apoptosis, erbb signaling, jak-stat signaling and map kinase signaling 
pathways (Figure 10). 
We integrated significant SNVs, CNVs, DEGs and DEGs in active subnetworks by 
performing multivariate Cox Proportional Hazards Regression (CPHR) analysis with 
LOOCV and Lasso penalty after univariate CPHR, we determined 12-gene expression 
signature (BCHE, CCNA1, CYP24A1, DEPTOR, MASP2, MGLL, MYO1A, PODXL2, 
RAPGEF3, SGK2, TNNI2, ZBTB16) which has 0.858 and 0.591 c-index score for 
training and test data, respectively. Moreover, this 12-gene expression signature had 
0.883, 0.813, 0.943 and 0.976 AUC values for 1, 2, 5 and 10-year survival prediction, 
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respectively, for training data. Same 12-gene expression signature had 0.479, 0.571, 
0.622 and 0.676 AUC values for 1, 2, 5 and 10-year survival prediction, respectively, for 
test data. We clustered the patients for both training and test analysis, into high-risk 
and low-risk group based on risk scores calculated by using expression levels and 
multivariate CPHR coefficients of 12 genes in signature. Kaplan-Meier survival analysis 
showed highly significant overall survival difference between high-risk and low-risk 
groups for both training data (p < 0.0001) and test data (p = 0.00055). 
All genes in 12-gene signature are cancer-related and play role in lung cancer pathways 
which are candidates of molecular targeting. BCHE (Butyrylcholinesterase) activity in 
lung adenocarcinoma is less than in adjacent non-cancerous tissue (Martinez-Moreno 
P. 2006); and BCHE is one of two potential diagnostic markers in plasma/serum for 
non-small cell lung cancer (Shin J. 2017). CCNA1 (Cyclin A1) is a cell cycle regulator 
protein and was down-regulated in non-small cell lung cancer and CCNA1 promoter 
was hypermethylated in 70% of lung tumors which has wild-type p53, but was not 
methylated in cells with mutant p53 (David S. Shames, 2006). CCNA1 plays a role in 
p53-mediated G2 cell cycle arrest and apoptosis in non-small cell lung cancer cells and 
upregulation of cyclin A1 resulted in apoptosis (Rivera A. 2006). However, Cho et al. 
determined that knock-down of CCNA1 using siRNA, induced apoptosis in non-small 
cell lung cancer cells (Cho N. H. 2006). CYP24A1 expression level was highly increased 
in lung adenocarcinoma compared to normal lung tissue samples and CYP24A1 
overexpression was associated with poorer survival, increased cell growth and invasion, 
and increased RAS protein expression in lung adenocarcinoma (Guoan Chen, 2010; 
Hiroe Shiratsuchi, 2016; NAN GE, 2017; Meng Li, 2019). Knockdown of CYP24A1 
significantly decreased cell proliferation resulted in tumor growth delay and smaller 
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tumor size with decreased RAS protein level, thus reducing phosphorylated AKT (Hiroe 
Shiratsuchi, 2016). DEPTOR (DEP domain-containing mTOR-interacting protein), a 
natural mTOR inhibitor, was downregulated by activation of EGFR signaling. EGFR 
inhibition by Gefitinib resulted DEPTOR accumulation. DEPTOR inhibited 
proliferation, migration, invasion and the tumor growth of lung adenocarcinoma. 
DEPTOR induction inhibited EGFR mediated tumor progression (Xuefeng Zhou, 
2016). DEPTOR depletion can induce EMT in cancer cells and DEPTOR plays a critical 
role in EMT regulation by BMK1 (Runqiang Chen, 2012). DEPTOR was also identified 
as one of the 77 clinically relevant predictive biomarker at TGFβ-EMT signature 
generated by microarray analysis of TGFβ-1 treated non-small cell lung cancer cells. 
TGFβ-EMT gene signature could predicted overall survival and metastasis-free survival 
in lung adenocarcinoma (Edna Gordian, 2019). MASP-2 (Mannan-binding lectin-
associated serine protease 2) is a plasma protein involved in lectin pathway of 
complement system which promotes cell dedifferentiation, proliferation, migration and 
reduced apoptosis. Complement activation in the tumor microenvironment enhances 
tumor growth and increases metastasis (Vahid Afshar-Kharghan, 2017). High MASP-2 
levels concentration in serum significantly correlated with recurrent cancer disease and 
with poor survival, thus the MASP-2 level had an independent prognostic value in the 
patients (Henriette Ytting, 2005). MBL/MASP complex activity was significantly 
increased in patients with colorectal cancer, too (H. Ytting, 2004). MGLL 
(Monoglyceride lipase) is highly expressed in aggressive human cancer cells and 
primary tumors, where it regulates a fatty acid network enriched in oncogenic signaling 
lipids that promotes migration, invasion, survival, and in vivo tumor growth (Daniel K. 
Nomura, 2010). MGLL expression was significantly reduced in the majority of primary 
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human lung cancers and primary colorectal cancers compared to normal tissues 
(Renyan Liu, 2018; H Sun, 2013). MGL suppressed colony formation in tumor cell lines 
and knockdown of MGL resulted in increased Akt phosphorylation. MGL plays a 
negative regulatory role in phosphatidylinositol-3 kinase/Akt signaling and tumor cell 
growth (H Sun, 2013). MGLL knock-out mice exhibited a higher incidence of neoplasia 
in lung (Renyan Liu, 2018). MYO1A (Myosin I a) expression was higher in ever smokers 
than in never smokers (Giulia Pintarelli, 2019). MYO1A had mutations and promoter 
hypermethylation in patients with colorectal cancer and gastric tumors; therefore, 
lower levels of MYO1A expression was associated with faster tumor progress and poor 
prognosis (Mazzolini 2012; Mazzolini 2013). Podocalyxin is an anti-adhesive 
transmembrane protein played role in the development of more aggressive breast and 
prostate cancer (9, 12 in Steven Sizemore, 2007). Podocalyxin (including PODXL1, 
PODXL2 and PODXL3) induction resulted in altered migration and invasion, increased 
MMP expression with increased MAPK and PI3K activity through forming a complex 
with Ezrin protein, in breast and prostate cancer (Steven Sizemore, 2007). Mammalian 
exchange protein directly activated by cAMP isoform 1 (EPAC1), encoded by RAPGEF3 
gene, acts as guanine exchange factor for Ras-like Rap small GTPases (Banerjee, 2015). 
EPAC1 expression was lower in lung cancer tissue compared to expression in normal 
specimens and associated with the degree malignancy and lymph-node metastasis 
(Qian Sun, 2018). SGK is one of three isoforms of the serum glucocorticoid regulated 
kinase family of serine/threonine kinases. SGK2 expression was upregulated in 
hepatocellular carcinoma and its downregulation inhibits cell migration and invasion 
(Junying Liu, 2017). Expression level of SGK1 was higher in squamous cell lung cancer 
and correlated with high grade tumors, tumors size and clinical stage (Claudia 
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Abbruzzese, 2012). Protein and mRNA expression of cardiac troponin I (TNNI3) were 
abnormally detected in non-small cell lung cancer tissues, lung adenocarcinoma cell 
line and lung squamous cell carcinoma cases while there was negative staining for 
TNNI3 in non-cancer lung tissues (Chao Chen, 2014). ZBTB16 (zinc finger and BTB 
domain containing 16), also known as the promyelocytic leukemia zinc finger protein 
(PLZF), was down-regulated in lymph node adenocarcinoma metastases and NSCLC 
samples by hypermethylation in the promoter region (Xiaotian Wang, 2013; Guang-
Qian Xiao, 2015). Overexpression of ZBTB16 in lung cancer cell lines inhibited 
proliferation and increased apoptosis while the depletion of cytoplasmic PLZF was 
correlated with high tumor grade, lymph node metastasis, higher tumor stage and 
shorter overall survival (Xiaotian Wang, 2013; Guang-Qian Xiao, 2015). ZBTB16 was 
also down-regulated in never smoker patients with lung adenocarcinoma (YUNQIAN 
HU, 2015) and non-small cell lung cancer high-metastatic cell line compared with the 
low-metastatic cell line (RUIYING SUN, 2019). 
 
Conclusions 
In this study we analyzed significant SNVs, CNVs and DEGs in active subnetworks, 
which have impact on overall survival of patients with lung adenocarcinoma in TCGA 
project. We determined 12-genes of which are strong candidates to be used as molecular 
signature for prediction of overall survival-based risk group of patients with lung 
adenocarcinoma. These genes can be used to cluster patients and determine the best 
candidates of drugs for the patient clusters which have different molecular nature. 
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These genes also have high potential for targeted cancer therapy of patients with lung 
adenocarcinoma. 
 
Methods 
Data 
Simple Nucleotide Variation, Transcriptome Profiling, Copy Number Variation and 
Clinical data of both 55 LUAD patients who have paired (both normal and tumor 
samples) RNAseq data and of 510 patients who have all four types of data was 
downloaded from TCGA harmonized database by using R/Bioconductor TCGAbiolinks 
package (Colaprico, 2016). We analyzed the genomic alteration data including Simple 
Nucleotide Variations, Copy Number Variations; and transcriptomic variations from 
RNAseq data, processed using the reference of hg38; and clinical data of LUAD patients 
(Table 7). 
Identification of Significant Simple Nucleotide Variations 
The Mutation Annotation Format (maf) file contained somatic mutations of all patients 
in TCGA LUAD project, was downloaded using TCGAbiolinks package. The other 
R/Bioconductor package, maftools (Mayakonda, 2018), were used to subset original 
maf file by tumor sample barcodes of patients of interest. Maftools package also 
summarizes the mutations and represents as summary plot and oncoplot. Significant 
mutated genes divided into two groups, oncogene (OG) or tumor suppressor gene 
(TSG), among tumor samples of 55 and 510 patients were identified seperately by using 
SomInaClust R package (Van den Eynden, 2015). SomInaClust works on the basic 
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assumption that important genes in tumor samples have clustered on sequence and 
high number of inactivating mutations because of the selective pressure during 
tumorigenesis. Based on this assumption, oncogenes have clustered mutations, while 
tumor suppressors have inactivating (protein truncating) mutations. SomInaClust uses 
a reference step in which background mutation rate and hot spots are determined for 
genes existing in reference mutation database such as COSMIC database (v88) (Forbes, 
2017). 
Identification of Significant Copy Number Variations 
The TCGA LUAD CNV dataset for primary solid tumor samples, generated by 
Affymetrix Genome-Wide Human SNP Array 6.0 platform, was downloaded using 
TCGAbiolinks package. The significant aberrant genomic regions in tumor samples of 
55 and 510 patients were identified separately by R/Bioconductor GAIA package 
(Morganella, 2011). NCBI IDs and Hugo Symbols of the genes with differential copy 
number were determined using biomaRt package (Durinck, 2009). 
Differential Expression Analysis (DEA) 
The Transcriptome Profiling data in mRNA expression level (as unnormalized HTSeq 
raw counts) of 55 LUAD patients who have paired samples was downloaded by 
TCGABiolinks package. Differentially expressed genes were determined with FDR 
adjusted p-values (q-values) in tumor samples (TP) according to normal samples (NT) 
of 55 LUAD patients by limma-voom method using limma (Ritchie, 2015) and edgeR 
(McCarthy, 2012) R/Bioconductor packages. NCBI IDs and Hugo Symbols of the 
differentially expressed genes determined by the biomaRt R package. 
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Active Subnetwork and Pathway Analysis 
We identified the active subnetworks of differentially expressed genes in tumor samples 
of 55 LUAD patients using R/Bioconductor DEsubs package (Vrahatis, 2016). The 
output of limma package containing differentially expressed genes with their Ensembl 
IDs and FDR adjusted p-values (q-values) were used as input of DEsubs package. 
DEsubs package determines and represents the active subnetworks with their graphs 
both at subnetwork and pathway levels. 
Statistical Analysis 
Clinical data of 55 and 510 patients was downloaded from TCGA database using the 
TCGAbiolinks package. Univariate Cox Proportional Hazards Regression analysis (Cox, 
1972) and logRank test (Mantel, 1966) were performed using survival R package for 
significant SNV containing genes, significant CNV containing genes, DEGs and active 
subnetwork genes to identify genes with prognostic ability. For the genes with 
prognostic ability (p value < 0.05), Cox proportional hazards model (LOOCV) with 
Lasso penalty was used to identify best gene signature among different combinations 
of molecular levels (SNV genes, CNV genes, DEGs and active subnetwork genes) by 
using glmnet R package. Concordance index (c-index) was performed using pec R 
package to validate the predictive ability of different gene signatures. The larger c-index 
is used to determine the gene signature which has more accurate predictive ability. 
Multivariate cox proportional regression analysis was performed using survival R 
package for genes of selected signature and risk score of each patient was calculated 
using coefficient and expression values of the genes. Then, patients were clustered into 
high-risk group and low-risk group and Kaplan-Meier (KM) survival curves (Kaplan & 
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Meier, 1958) were generated using survminer R package to demonstrate the overall 
survival of risk groups stratified based on gene signature. ROC curve analysis was also 
performed for risk scores calculated based on selected gene signature by using 
survivalROC R package. 
Significant differences in tumor stages, mutation counts and expression levels of 
patients in the high-risk and low-risk groups were identified using ggstatsplot R 
package. In order to validate the prognosis risk signature, the risk scores of 442 TCGA 
patients with LUAD were calculated using the expression values of gene signature and 
their coefficient values from multivariate cox proportional regression analysis. 
Similarly, 442 patients (after exclusion of 55 and other patients with missing data from 
510 patients) were clustered into high-risk and low-risk groups and the overall survival 
difference between the two groups of patients was assessed by KM survival curve. 
Significance level used for identification of genes containing copy number variations 
and differentially expressed genes, was 0.01 for FDR corrected q-value. Significance 
level was 0.05 for FDR corrected p values (q value) for identification of genes 
containing significant single nucleotide variations; and was 0.05 for p-values for active 
subnetwork and pathway analysis, and for all statistical analysis. 
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Figure 19. The workflow of construction and validation of the prognosis gene signature 
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